Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could your home be making your lung disease worse?

NCT ID NCT07457502

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at 100 adults with fibrosing interstitial lung diseases (a type of lung scarring) to see if things like mold, dust, air pollution, and other home factors make the disease progress faster. Researchers will compare patients whose disease is getting worse to those whose disease is stable. The goal is to better understand how the home environment affects lung health and to help patients reduce harmful exposures.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2023

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The recruited patients will be divided into two groups: * The "case" group will consist of patients with a fibrosing interstitial lung disease (ILD) who meet one of the criteria for fibrotic progression during the 6 months prior to inclusion. * The "control" group will be composed of patients with a fibrosing ILD who do not meet any of the criteria for fibrotic progression during the 6 months prior to inclusion. The proposed criteria for progression, which will be used in our project, are: Relative decrease in FVC ≥ 10%, Relative decrease in FVC ≥ 5% and a decrease in DLCO ≥ 15%, Relative decrease in FVC ≥ 5% and worsening of fibrotic signs on a scan, Relative decrease in FVC ≥ 5% and worsening of symptoms, Worsening of symptoms and fibrotic signs on a scan.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient aged over 18 years * Patient affected by one of the following interstitial lung diseases (ILDs): Idiopathic Pulmonary Fibrosis (IPF), Nonspecific Interstitial Pneumonia (NSIP), Pneumoconioses, ILDs associated with autoimmune features, Pleuroparenchymal Fibroelastosis (PPFE), Chronic Hypersensitivity Pneumonitis (CHP) whose etiology is not primarily related to the domestic environment, Stage 4 fibrosing sarcoidosis, unclassifiable ILDs. * ILD patient with progressive fibrosis over the past 12 months (case group) * ILD patient with non-progressive fibrosis over the past 12 months (control group) * Patients without reduction in the treatment of interstitial lung disease in the 12 months prior to inclusion, patients without treatment can be included * Matching "1 progressive fibrosis" / "2 non-progressive fibrosis": * Same ILD diagnosis * Use of antifibrotic treatment for both paired patients or absence of antifibrotic treatment for both paired patients * Both patients should preferably be matched within 3 months to limit significant contrasts in lifestyle and housing use related to the season * Patient who has received information about the protocol and does not object to participating * Patient affiliated with or beneficiary of a social security scheme or universal health coverage Exclusion Criteria: * Patient who has already received advice from a CMEI (Environmental and Occupational Medicine Consultation Center) in the past 12 months * Patient who has recently moved into their home (less than 1 year) * Patient living less than 6 months per year in the home to be investigated * Patient followed in psychiatry for a severe condition * Patient who does not speak French and is not accompanied by a person who shares their home and speaks French to act as a translator * Patient refusing to consent to participate in the research * Patient not living in Île-de-France * Patient with non-chronic Hypersensitivity Pneumonitis related to the domestic environment * Patient with sarcoidosis (except stage 4 fibrosing sarcoidosis) * Adult patient under legal protection and unable to give consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Assess cmei recommendations' impact on respiratory health are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hôpital Paris Saint Joseph

    RECRUITING

    Paris, Paris, 75014, France

  • Hôpital de Tenon

    RECRUITING

    Paris, Paris, 75020, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.